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Multidrug resistant tuberculosis (MDR-TB) is deﬁned as a Mycobacterium tuberculosis strain resistant to
two or more ﬁrst-line anti-tuberculous drugs. Tuberculosis (TB) is a global threat to society despite
improvement in therapy as it continues to be an economic burden especially in underdeveloped coun-
tries. The downfall of global economics and growing travel destinations in developing countries has
escalade the exposure of organism not previously encountered in industrialized nations. Most cases of
MDR-TB are reported on immunosuppressed patients with risk factors and from endemic areas.
Nevertheless new strains with higher transmission degree are emerging as a threat in patients who have
low risk factors for the development of MDR-TB.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Multidrug resistance is deﬁned as resistance of Mycobacterium
tuberculosis of two or more ﬁrst-line anti-tuberculous drugs that
include isoniazid and rifampicin [1]. The most recent estimates
suggest that globally there were about 489,000 case of multidrug-
resistant TB [2]. Multidrug-resistance can be classiﬁed as primary
or acquired [3]. Primary is deﬁned as resistance in patients never
been exposed to anti-tuberculous drugs treatment, whereas ac-
quired resistance occurs in patients with prior exposure to anti-
tuberculous drugs for at least one month and in those with treat-
ment failures and relapses [3]. Before the early 1990s multidrug-
resistant tuberculosis was not a mayor public health problem [4].
Interestingly, multi-drug resistance started appearing in patients
with M. tuberculosis infection soon after the introduction of effec-
tive anti-tuberculous drugs [5].
Factors that predispose a patient to the development of
multidrug-resistant tuberculosis include incomplete or inadequate
treatment, failure to identify pre-existing resistance and failure to
identify an appropriate adherence to treatment. Factors favoringendros, Bayamon, PR, 00961,
Rivera).
Ltd. This is an open access article uthe spread of tuberculosis, include increasing high-risk groups, the
elderly, prisoners, immigrants and drug addicts [1]. Certain host
genetic factors and coexistent HIV infection may also predispose to
the development of multidrug-resistant tuberculosis [1].
The patient presented in this case was diagnosed at ﬁrst with
susceptible TB and was treated with ﬁrst line anti-tuberculous
drugs with good clinical response. Unexpectedly, during the
course of treatment was found positive for MDR-TB. The initial
culture ofMycobacterium tuberculosis did not exhibit any resistance
to anti-tuberculous drugs, the patient is an immunocompetent host
and treatment fulﬁlled the standards of care including proper
adherence. Moreover, the patient had three negative sputum
samples for acid-fast bacilli (AFB) and cultures during initial
treatment. Patient was retested due to recurrence of symptoms and
positive sputum for AFB smear and cultures lead to the genomic
study of the organism. Results were consistent with a new strain
MDR-TB not reported in the United States of America or the
Caribbean. In 2014, theWorld Health Organization (WHO) reported
40 cases tested for suspected MDR-TB in Puerto Rico and only our
case was conﬁrmed to be MDR-TB [6].
2. Case presentation
We present the case of a 59-year-old male patient with past
medical history of Diabetes Mellitus type 2 who developednder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Chest x-ray posterior-anterior view shows right upper lung opacity.
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2012. Within the next 7 months patient had worsening of symp-
toms with rapid weight loss of 55kg (121bs) associated fever, chills,
night sweat, loss of appetite and relentless weakness. Patient had
traveled only to Ecuador for vacation with his family in 2010.
During this travel he denied exposure to sick contacts or crowded
household conditions. A chest x-ray and PPD skin test was per-
formed by his primary care physician for the initial evaluation of
symptoms. The PPD revealed no skin induration. Chest x-ray
showed multiple pulmonary nodules with no obvious cavitary
lesion. Patient was referred to a pulmonary specialist for further
evaluation. He underwent bronchoscopy that resulted inconclusive
and the patient has lost to follow-up.
In mid-2013, because of worsening of his symptoms as
described above he returned to the pulmonary disease specialist
who repeated the bronchoscopy due to suspected malignancy vs.
infectious process. Samples from the bronchoalveolar lavage had
positive AFB smear, with positive culture growth forM. tuberculosis.
Initial culture resulted pansensitive for TB. Other studies were
remarkable for an indeterminate Quantiferon-TB Gold test (see
Table 1), chest x-ray with right upper lung opacity and chest CT
scan showing right upper lobe consolidate with central cavitation
(see Figs. 1 and 2). He was placed on airborne isolation and started
in 4 anti-tuberculous drugs regimen including isoniazid, pyr-
azinamide, ethambutol, and rifampin. After 36 days of treatment
and 3 negative sputum samples for AFB smear the patient was
removed from negative pressure room, airborne precaution and
discharged home.
The patient was followed by the Department of Health (TB of-
ﬁce) as outpatient with Direct Observed Therapy (DOT). Two
months after been discharged form hospital and while still on TB
treatment symptoms reappeared. For this reason patient was
readmitted and repeated sputum cultures for M. tuberculosis were
done on January 2014. Samples sent to the Centers of Disease
Control (CDC) found to have multidrug resistant tuberculosis with
resistance to isoniazid, rifampin, ethambutol and streptomycin.
Genotype G24767 revealed the ﬁrst of its kind genomic sequence
not classiﬁed in the known cluster of Puerto Rico nor in the United
States Population. The patient was hospitalized and started on
second line anti-tuberculous drugs which included linezolid, lev-
oﬂoxacin, amikacin and cycloserine. The patient remained in hos-
pital isolated for 46 days until 3 negative sputum for AFB smear
were reported, but had to continue on at least three effective drugs
and one injectable after culture conversion. The patient has at this
point completed the 18 months after culture conversion, is symp-
tom free and has gained all his lost weight.Fig. 2. Chest CT scan shows right upper lobe consolidate with central cavitation.
3. Discussion
Multidrug-resistant tuberculosis is deﬁned as disease caused byTable 1
Laboratories.
Absolute CD4 helper 500
% CD 4 55.5
Absolute CD8 95
% CD 8 10.5
CD4/CD8 5.29
HIV Non-reactive
IgA 881
IgM 104
IgG 2069
Quant TB Ag 0.87
Quant Nil 0.14
Quant TB Gold Indeterminatestrains ofMycobacterium tuberculosis that are resistant to both ﬁrst
line anti-tuberculous drugs isoniazid and rifampicin. MDR-TB are
serious threats to the progress that has been made in the control of
tuberculosis worldwide over the past decade [7]. Statistical data
has shown more than 400,000 cases of MDR-TB worldwide with a
mortality ratio of 30 per 100 affected individuals. This means that
every day there are about 400 deaths related to MDR-TB [8,9].
Globally, in 2014 the WHO reported an estimate of 190,000 death
related to MDR-TB [10]. The highest proportions of MDR-TB cases,
and the most severe drug-resistance patterns, appear in the
countries of the former Soviet Union [7]. High prevalence among
new cases were found in China, and Israel as well [1]. This alarming
prevalence of resistance could be attributed to poor TB control by
deﬁcient use of national guidelines, immigration of patients from
areas of high resistance and outbreak of resistant disease [1].
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drug resistance attributed to M. tuberculosis. The term ‘primary’ is
resistance in a new patient that has never been exposed to anti-
tuberculous drugs and ‘acquired’ is resistance in a previously
treated patient [11]. The main causes of acquired resistance are
poor patient management, non-adherence to the prescribed
regimen, inadequate national program or some combination of
these three [11]. The most powerful predictor for MDR-TB is a
history of previous treatment for TB [1,11]. However, another less
common factors for primary resistance is host predisposition as
seen in HIV-positive patients, particularly to rifampin [12].
The diagnosis of MDR-TB is made by sensitivity tests showing
resistance to isoniazid and rifampicin. Three conventional methods
are available for sensitivity; the absolute concentration method,
resistance ratio method, and the proportion method [1]. These
conventional methods requires up to 6e8 week for sensitivity re-
sults to be available. Newer molecular methods are currently
available with faster sensitivity results ranging from 48hr (gene
assay system) and 10 days (radiometric methods). These newer
methods are not readily available in all laboratories [1].
In terms of management, it is important to recognize that MDR-
TB curable rates are low and may be fatal. The management in-
volves a complicated treatment regimen that requires trained and
experienced persons because inappropriate management can have
life-threatening results [13]. When suspected MDR-TB either by
epidemiologic or history information, sputum samples must be
send for culture and sensitivity testing [1]. Empirical regimens
employing second line reserve drugs must be initiated pending
sputum culture report as recommended by the American Thoracic
Society (ATS), CDC, Infectious Diseases Society of America (IDSA) or
WHO treatment regimen [14]. Further MDR-TB therapy will depend
on sensitivity report. The national guidelines also states that a
single drug should never be added to a failing regimen. Further-
more, when initiating, at least three previously unused drugs must
be employed to which there is in vitro susceptibility [14]. MDR-TB
treatment is based in the use of second line drugs. DOT plays also
an important role in the control of MDR-TB. This practice not only
aims to cure the patient but also to reduce the risk of further
spreading and resistance ensuring treatment compliance by su-
pervised administration of drugs [11]. Patients receiving therapy for
MDR-TBmust be closely followed up. Response to treatment should
be assess by clinical, radiological and microbiological parameters.
Likewise, attention must be focused on periodic monitoring for
adverse drug reactions [1].
We have presented an interesting but at the same time alarming
case of a new strain MDR-TB G24767 genomic pattern resistant to
ﬁrst line drugs (isoniazid, rifampin and ethambutol) and borderline
secondary drugs (streptomycin) in a patient who was otherwise
healthy. The only risk factor in our patient for MDR-TB was current
use of anti-tuberculosis drugs. The patient received ﬁrst linetreatment according to the national guidelines for susceptible TB
and still became infected with a new strain MDR-TB while
completing therapy. Then, is there a genetic factor involved with
new adaptive capacity for such fast mutation inM. tuberculosis even
with the appropriate treatment regimen or it is just a new era of
MDR-TB?Whichever the reason is, this raise a concern for a serious
threat. TB is an old disease known to be a major public health issue
for decades. For this reason we must create awareness among
health care professionals of this existing fact, this way all new cases
of MDR-TB can be notiﬁed for genomic sequence and immunoge-
nicity studies to understand virulence and drug resistance. Simi-
larly, all cases must be managed appropriately to reduce spreading,
mortality rates, and more resistance.Financial disclosure and conﬂict of interest
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